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Abstract 
Background: Inconsistencies in outcome reporting and frequent omission of patient-centered 
outcomes can diminish the value of trials in treatment decision-making. We identified critically 
important outcome domains in kidney transplantation based on the shared priorities of 
patients/caregivers and health professionals. 
 
Methods: In a 3-round Delphi survey, patients/caregivers and health professionals rated the 
importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and 
provided comments. During Round 2 and 3, participants re-rated the outcomes after reviewing their 
own score, the distribution of the respondents’ scores, and comments. We calculated the median, 
mean, and proportion rating 7-9 (critically important), and analyzed comments thematically. 
 
Results: 1018 participants (461 [45%] patients/caregivers and 557 [55%] health professionals) from 
79 countries completed Round 1, and 779 (77%) completed Round 3. The top eight outcomes that 
met the consensus criteria in Round 3 (mean ≥7.5, median ≥8 and proportion >85%) in both groups 
were graft loss, graft function, chronic rejection, acute rejection, mortality, infection, cancer 
(excluding skin) and cardiovascular disease. Compared with health professionals, patients/caregivers 
gave higher priority to six outcomes (mean difference of 0.5 or more): skin cancer, surgical 
complications, cognition, blood pressure, depression, and ability to work. We identified five themes: 
capacity to control and inevitability, personal relevance, debilitating repercussions, gaining 
awareness of risks, and addressing knowledge gaps. 
 
Conclusions: Graft complications and severe comorbidities were critically important for both 
stakeholder groups. These stakeholder-prioritized outcomes will inform the core outcome set to 
improve the consistency and relevance of trials in kidney transplantation.  
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INTRODUCTION  
 
Over the past 50 years, remarkable progress has been made in kidney transplantation, largely owing 
to treatment advances and the growing number of trials in this area (1). Substantial reductions in 
rates of acute rejection have seen commensurate improvements in one-year graft survival (2,3). 
However, kidney transplant recipients depend on lifelong immunosuppressive therapy, which is 
associated with increased risks of life-threatening comorbidities including cardiovascular disease, 
diabetes, and cancer. An estimated 50% of patients have died with a functioning graft ten years after 
transplantation, mostly due to the consequences of over immunosuppression (4,5). While transplant 
may improve patient quality of life compared with dialysis, immunosuppression-related side effects 
can diminish these potential benefits (6). Such challenges draw attention to the need for evidence-
informed shared decision making based upon trials that consistently report outcomes that are 
meaningful to both patients and clinicians (7).  
 
Trials in kidney transplantation are often short-term, and important outcomes such as mortality, graft 
loss and kidney function are inconsistently and incompletely reported in randomized trials in kidney 
transplantation; with just one-third reporting all three outcomes (8). Only 58% of trials report 
infection and 48% of trials report cancer (9). Less than 2% of trials of maintenance 
immunosuppression interventions report quality of life outcomes, with nearly all favoring the 
intervention (10). The heterogeneity of outcomes, many of which may not be directly relevant to 
patients, and selective reporting of outcomes diminishes the reliability and relevance of clinical trials 
for decision-making (11). 
 
These problems are well recognized across many areas in healthcare, which has driven the 
development of core outcome sets, defined as an “agreed minimum set of outcomes to be reported in 
all trials” addressing a specific condition (12). The Standardized Outcomes in Nephrology (SONG) 
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initiative was launched in 2014 to establish core outcomes across all stages of chronic kidney disease 
(CKD) including kidney transplantation (SONG-Tx) (13). As part of the SONG-Tx initiative, this 
study aimed to gain consensus among patients, caregivers and health professionals on critically 
important outcomes for trials in kidney transplantation. A core outcome set can improve the 
reporting of outcomes in trials permitting reliable comparisons of the effect of interventions across 
trials, and enhancing the usability and uptake of trial evidence in decision-making. 
 
METHODS 
 
Study design 
 
The Delphi technique is a validated approach for establishing consensus on core outcomes (14-18) 
and consists of iterative surveys with anonymous responses to gain consensus among an “expert” 
panel (19,20) (Supplementary File Figure S1). 
 
Participant selection and recruitment 
 
Adult patients/caregivers (aged 18 years or over) and health professionals with an interest or 
experience in kidney transplantation were eligible to participate. Patients/caregivers included kidney 
transplant recipients, patients with CKD Stages 1-5, or on dialysis, their caregivers, family members, 
and living kidney donors. Health professionals included physicians (nephrologists, surgeons, and 
psychiatrists), nurses, allied health professionals (psychologists, social workers, dieticians, and 
pharmacists), policy makers/regulators, researchers, and industry. 
 
To be broadly inclusive, we used multiple recruitment strategies. Patients/caregivers were recruited 
by site investigators at participating hospitals, patient organizations worldwide  (Supplementary File 
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Table S1) using standardized invitation fliers, the SONG Network database by email, and via 
snowball sampling which included the use of social media. Health professionals were recruited 
through professional organizations (Supplementary File Table S1) via a standard invitation email to 
their membership list, investigator networks, and the SONG database. The invitation directed 
participants to register their email on the SONG website to receive an email invitation with the 
unique survey link. The University of Sydney (2015-228), Baylor College of Medicine (H-37406), 
University of Calgary (REB15-1875), Salford Royal NHS Trust (13082B) and Sydney West Area 
Health Services (HREC2009/6/4.15) provided ethics approval. 
 
Data collection 
 
Selection of outcome domains: We identified the outcome domains from a systematic review of 
outcomes reported in trials in kidney transplant recipients, studies on kidney transplant recipient 
preferences for outcomes (21), and studies focusing on patient-reported outcomes (22–23). The list 
of outcomes was reviewed by the investigators, and piloted among eight patients. We programmed 
and administered the survey online using LimeSurvey from February to June 2016 (24). The survey 
was conducted in English. 
 
Round 1: Round 1 included 35 outcome domains (Supplementary File Table S2). Participants rated 
the importance of each outcome domain on a 9-point Likert scale using the GRADE scale (Rating 1 
to 3 indicated  “limited importance”, 4 to 6 “important, but not critical,” and 7 to 9 “critical 
importance”) (25). Free text boxes were provided for comments and participants could suggest new 
outcomes. Outcomes with a mean and median of more than or equal to seven were taken through to 
Round 2. New outcomes suggested by more than 10% of the participants would be included in the 
next round. 
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Round 2: Participants re-rated each outcome and provided (optional) comments. Participants 
reviewed their own score from Round 1, and the distribution of the group responses on a column 
graph displayed by patients/caregivers, health professionals, and the weighted score of both groups 
combined. Participants were shown the comments from patients/caregivers and health professionals. 
If outcomes had a mean and median score of more than 7, and more than 50% of participants rated 
the outcome 7 to 9, we retained those outcomes for Round 3. 
 
Round 3: Participants were provided with their own score, the group responses and comments as per 
Round 2 and asked to re-rate the final set of outcomes. To assess the relative importance of 
outcomes, participants also completed a forced ranking exercise and ordered outcomes in order of 
importance using a drag and drop function (26).  
 
Data analysis 
 
Quantitative analysis: We assessed the mean, median, and the proportion of participants who rated 7 
to 9 for each outcome across all rounds, and separated by patients/caregivers and health 
professionals. We compared the mean difference in rating scores between both stakeholder groups 
with a Wilcoxon signed rank test or a t test, significance at p<0.05. We performed subgroup analysis 
by country and age. For the forced ranking scores, we calculated the median and interquartile range 
(IQR) to determine the rank of each outcome. Statistical analyses were undertaken using R version 
3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).  
 
Definition of consensus for core outcomes: An a priori definition of consensus was not possible 
because of the unknown distribution of scores for the outcome domains. For feasibility, we aimed to 
identify the top 3-5 outcome domains indicated as critically important by both stakeholder groups. 
“Consensus” for a critical outcome domain was based on both stakeholder groups having a median 
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score of greater than or equal to 8,  a mean score greater than or equal to 7.5, the proportion of 
participants rating the outcome as ‘critically important’ being greater than or equal to 75%, and a 
median score of less than 10 in the forced ranking question. 
 
Qualitative analysis: We imported the comments into HyperRESEARCH (Version 3.7, Randolph 
MA United States) software for qualitative data analysis. Using thematic analysis, KEM coded the 
text and inductively identified themes focusing on reasons for ratings, changes in ratings across 
rounds, and differences between stakeholder groups. Two investigators (BS and AT) who read the 
qualitative data, reviewed the preliminary analysis to ensure that the themes captured the range and 
depth of data. 
 
RESULTS 
 
Participant characteristics 
 
In round 1, 1018 people from 78 countries participated, of whom 461 (45%) were patients/caregivers 
and 557 (55%) were health professionals. Round 2 was completed by 844 (83% response rate) 
participants from 70 countries, of whom 387 (46%) were patients/caregivers and 457 (54%) were 
health professionals. Round 3 was completed by 779 (77% response rate) participants with 360 
(46%) patients/caregivers and 419 (54%) health professionals from 68 countries. Overall, the 
participant characteristics were consistent from rounds 1 to 3 (Table 1 and 2). 
  
Of the 360 patients/caregivers who completed all three rounds, 251 (69%) were kidney transplant 
recipients, 32 (9%) patients on dialysis, 17 (5%) patients not on any kidney replacement therapy, 35 
(10%) living kidney donors, and 27 (7%) were caregivers/family members. The patients/caregivers 
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were from 21 countries. Of the 419 health professionals, 281 (59%) were nephrologists, 61 (13%) 
researchers, and 49 (10%) nurses. Health professionals were from 64 countries. 
 
Ratings and ranking 
 
Round 1: The mean and median scores for each of the 35 outcome domains and proportion of 
participants scoring outcomes as 7-9 (critical importance) for each outcome are included in the 
Supplementary Table S3. For patients/caregivers, the four outcomes with the highest mean scores 
were: graft loss (8.3, standard deviation [SD] =1.3), graft function (8.1 [1.3]), chronic graft rejection 
(7.9 [1.5]) and acute graft rejection (7.9 [1.6]). For health professionals, the four top outcomes were 
graft loss (8.4 [1.8]), mortality (8.3 [2.3]), graft function (7.9 [1.7]), and chronic graft rejection (7.8 
[1.6]). Thirteen outcomes had a mean or median score of less than 7 among both groups and were 
excluded from round 2 (Supplementary Table S3). None of the new outcomes were suggested by 
more than 10% of the participants (Supplementary Table S4). 
 
Round 2: The mean and median scores for each of the 22 outcome domains and proportion of 
participants scoring the outcome as 7-9 (critical importance) for each outcome are included in the 
Supplementary Table S5. For patients/caregivers, the four outcomes with the highest mean scores 
were: graft loss (8.6 [0.8]), chronic graft rejection (8.5 [0.9]), graft function (8.5 [1.0]) and acute 
graft rejection (8.2 [1.2]). For health professionals, the four highest were graft loss (8.8 [1.5]), 
mortality (8.7 [1.1]), graft function (8.4 [1.0]), and chronic graft rejection (8.3 [0.9]). Six outcomes 
were excluded from round 3 as they had a mean and median score ≤7 with less than 50% of the 
participants rating the outcome 7 to 9 (Supplementary Table S5).  
 
Round 3: The mean and median score for each of the 16 outcome domains and the proportion of 
participants scoring the outcome as 7-9 (of critical importance) for each outcome are shown in 
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Supplementary Table S6 and Figure S2. For patients/caregivers, the four outcomes with the highest 
mean scores were: graft loss (8.8 [0.6]), chronic graft rejection (8.6 [0.8]), graft function (8.6 [0.9]) 
and acute graft rejection (8.3 [1.0]). For health professionals, the four highest were graft loss (8.9 
[0.4]), mortality (8.8 [0.7]), graft function (8.6 [0.7]), and chronic graft rejection (8.5 [0.8]). Median 
rank scores (shown in Supplementary Figure S3) and Inter Quartile Ranges (IQR) were calculated 
from the forced ranking exercise. Based on the median rank scores and IQR, the four most important 
outcomes for patients/caregivers were graft loss (median score 3 [IQR 2-5]), chronic graft rejection 
(3 [2-5]), acute graft rejection (4 [2-6]) and graft function (5 [3-7]). For health professionals the four 
most important were graft loss (3 [2-3]), mortality (3 [1-4]), graft function (5 [3-6]), chronic graft 
rejection (5 [3-6]).  
 
Consensus: Eight of the 16 outcomes in round 3 met all four consensus criteria (mean rating ≥ 7.5, 
median rating ≥ 8, proportion of 7 to 9 rating scores ≥ 75%, median rank score < 10) in both 
stakeholder groups. These were: graft function, mortality, acute graft rejection, chronic graft 
rejection, graft loss, infection, cardiovascular disease and cancer (non-skin). Figure 1 depicts all 16 
outcomes from Round 3 against the four consensus criteria. 
 
Changes in scores from round 1 to 3 
 
The eight outcomes that fulfilled the consensus criteria were the same across the three rounds for 
both stakeholder groups. For patients/caregivers, the mean rating scores for 15 of the 16 outcomes in 
round 3 increased and only the score for blood pressure decreased. For health professionals, the mean 
scores for 14 of the 16 outcomes in Round 3 increased. The results are presented in Figures 2 and 3. 
 
Differences between stakeholder groups 
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The mean differences in ratings between both stakeholder groups across all rounds are shown in 
Figure 4. Patients/caregivers rated 11 outcome domains higher than health professionals: skin cancer 
(mean difference 1.0, p<0.001), surgical complications (0.7, p<0.001), cognition (0.6, p<0.001), 
blood pressure (0.6, p<0.001), depression (0.5, p<0.001), ability to work (0.5, p<0.001), acute graft 
rejection (0.3, p<0.001), non-skin cancer (0.3, p<0.001), infection (0.3, p<0.001), diabetes (0.2, 
p<0.001), and chronic graft rejection (0.1, p=0.022). Two outcomes were rated higher by health 
professionals: mortality (0.4, p<0.001) and hospitalization (0.2, p=0.033). The subgroup analyses for 
countries with more than 10 participants for outcomes rated higher by patients/caregivers (i.e. 
outcomes with a mean difference of 0.5 or more) are shown in Table S7. There were no differences 
in the rating of these outcomes across countries except for cognition and depression. 
 
Themes from comments 
 
We identified five themes that reflected the reasons, changes and differences in the rating of 
outcomes: capacity to control and inevitability, personal relevance, debilitating repercussions, 
understanding and gaining awareness of risks, and addressing critical knowledge gaps. The 
description of the themes in the following section applies to both stakeholder groups unless 
otherwise specified, and supporting quotations are provided in Table 3. 
 
Capacity to control and inevitability: Although participants recognized some outcomes such as blood 
pressure or skin cancer as important, these were rated of relatively lower importance if perceived as 
preventable, treatable, or non-life threatening. Across rounds, some participants decreased their 
ratings as they realized that certain outcomes could be feasibly improved – “I changed my answer. 
It´s critical, but experienced surgeons make miracles happen.” For patients, some outcomes were 
considered of lower importance if they were inevitable – “death comes to us all, but maintaining 
quality of life while living is more important.”  
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Personal relevance: Participants considered the importance of outcomes in terms of the 
patient/caregivers’ life stage, health status, and personal experience, and this was maintained across 
rounds. For example, patients who were retired rated ability to work of lower importance. However, 
some recognized that fertility and ability to work would be an important outcome for younger 
people, and thus adjusted their rating to be “sympathetic” to other patients in different stages of life. 
 
Debilitating repercussions: Outcomes seen as severely debilitating, distressing, or which would lead 
to serious comorbidities or hospitalization were rated of higher importance. For patients, graft loss 
meant a return to dialysis, which was described as “devastating” and “worse than the fear of death.” 
In contrast, some health professionals agreed that losing the graft was a “main hard endpoint”, but 
“relative to death [it] cannot receive the highest rating.” 
 
Understanding and gaining awareness of risks: Patients/caregivers increased their ratings across 
rounds as read comments from health professionals and became “enlightened” about the risks of 
outcomes. Outcomes were rated higher if they learned that it was associated with a greater risk of 
graft loss and chronic graft rejection – “I'm naturally going to increase my rating if the 
pro[fessional]'s think it's critical.” Health professionals expressed appreciation and “respect” of the 
importance of outcomes to patients, namely psychosocial and disabling outcomes – “underestimated 
the importance based on patient feedback.”  
 
Addressing critical knowledge gaps: Participants recognized the unresolved challenges of preventing 
complications including rejection, graft function, cancer, infection, and diabetes, which prompted 
them to assign higher importance to these outcomes. Health professionals suggested that “long 
standing issues” that lacked evidence should also be high priorities for research and would benefit 
patients e.g. ability to work.  
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DISCUSSION 
 
The outcomes of critical importance for patients/caregivers and health professionals were graft loss, 
graft function, acute graft rejection, chronic graft rejection, mortality, cardiovascular disease, 
infection, and cancer (non-skin). Overall, the results were congruent between the two stakeholder 
groups, with the same top eight outcomes. Graft-related outcomes comprised the top four for both 
patients/caregivers and health professionals, consistent with research priority setting studies (27–29). 
For patients, returning to dialysis was a devastating consequence of graft failure that could even be 
worse than death. The critically important outcomes based on consensus echo the foremost 
challenges in transplantation, specifically, balancing graft survival and graft complications, with the 
risk of severe medical comorbidities (27,30–34). The other outcomes that remained in the final round 
of the Delphi survey were mostly clinical complications, of which skin cancer, diabetes, surgical 
complications, cognition, and depression, were more important to patients/caregivers than they were 
to health professionals. Only one patient-reported outcome (ability to work) remained in round 3. 
This may reflect the gains in quality of life owing to kidney transplantation compared with dialysis, 
and that various dimensions of quality of life are implicit in graft outcomes and severe medical 
complications. 
 
While mortality was rated critically important for both stakeholder groups, the mean rating score was 
higher for health professionals (8.3) and ranked second after graft loss, compared with 
patients/caregivers (7.6) where mortality ranked fifth (below all the graft related outcomes). This 
discrepancy could be due to differences in how patients/caregivers and health professionals 
conceptualize death. Free text comments suggest that patients accept death as unavoidable, beyond 
their control, and therefore place greater importance on having a good quality of life. For health 
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professionals, patient survival was entrenched as their primary goal of care and deemed to be the 
principal hard endpoint (35).  
 
Patients and caregivers placed greater importance on skin cancer, surgical complications, cognition, 
depression, blood pressure, and ability to work, compared with health professionals. The discrepancy 
in the prioritization of skin cancer may reflect geographical variations in the risk of skin cancer. We 
noted that patients/caregivers in countries with public campaigns for skin cancer prevention (United 
States, South Africa, Canada and Australia (36–39)), on average, rated skin cancer as critically 
important. Patients and caregivers expressed some fears about surgical complications, which may in 
part explain the higher rating. Whilst mental health and cognition outcomes improve after kidney 
transplantation, kidney transplant recipients are still at higher risk of cognitive impairment compared 
with the general population (34,40–42). This may also be attributable to the growing population of 
older recipients in whom cognitive decline is more prevalent (43). Such problems remain under-
recognized and few studies have addressed the effect of transplantation on cognitive function 
(44,45). Blood pressure was initially rated highly, then decreased from round 1 to 3. From the 
comments, we speculate that patients became more aware that blood pressure was manageable after 
reading comments from health professionals. Ability to work was critically important to 
patients/caregivers across countries, some of whom regarded working as a key measure of transplant 
success and return to normality. 
 
Unlike for hemodialysis, patient-reported outcomes were not prioritized as highly in kidney 
transplantation. In the Delphi survey on hemodialysis, ability to travel and dialysis-free time were 
rated markedly higher by patients/caregivers than providers (17). Also, a wider range of lifestyle 
patient-reported outcomes remained critically important in hemodialysis for both stakeholder groups 
(ability to travel, dialysis-free time, post-dialysis fatigue, mobility, fatigue, social impact, pain, and 
ability to work). These differences between haemodialysis and kidney transplantation may be 
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indicative of the considerable improvements in quality of life achieved through kidney transplant. 
The overriding goal for kidney transplant recipients was to protect their graft in order to maintain 
their quality of life and remain free from the constraints and distress of dialysis (46,47). 
 
The consensus between patients/caregivers and health professionals supports the inclusion of graft 
outcomes and medical comorbidities in a core outcome set for kidney transplantation. However, the, 
dominant focus on the clinical challenges of kidney transplantation may have led to patient-reported 
outcomes being assigned a lower rating score. For example as quality of life is markedly improved 
by transplantation, compared to dialysis, it could be assumed as a given provided the graft continued 
to function. This is pertinent given the increasing emphasis on including patient-reported outcome 
measures in trials, to assess how patients feel and function (48). Moreover, patient-reported outcome 
measures are now required by regulators such as the U.S. Food and Drug Administration to support 
claims for medical product labeling (49). Thus, we recommend to include a patient-reported outcome 
domain in the core set. Although “ability to work” was the highest rated patient-reported outcome 
domain in round 3, this may have lower personal relevance to, for example, patients who are 
studying or retired. Thus, further work is needed to refine this outcome domain such that it is more 
broadly relevant to all kidney transplant populations, irrespective of age, gender, and socio-economic 
factors.  
 
Compared with other Delphi surveys used to establish core outcomes, our sample size is large with a 
broad representation of different stakeholders across 79 countries and had a high response rate of 
77% by round 3 (46,47). Our findings also included qualitative data to provide further insights into 
the meaning, reasons and interpretations of the outcomes by participants. However, there are some 
potential limitations. For technical reasons and feasibility, we administered the survey in English-
language, which precluded a larger representation of patients and caregivers from non-English 
speaking countries with different health systems. Therefore, the generalisability to non-English 
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speaking countries may be uncertain. Also, the survey could only be accessed online to facilitate 
broader dissemination and minimise data entry errors, which limited participation to those with 
internet access and computer literacy. 
 
Core outcomes should be reported in all trials in kidney transplantation because they are relevant and 
important to patients and clinicians. Patients and clinicians want to know the effect of an intervention 
on outcomes they regard as critically important irrespective of whether the intervention makes a 
difference. Researchers are not required to use a core outcome as a primary endpoint to estimate the 
sample size required to adequately power a study. Also, researchers may add other outcomes based 
on other considerations including responsiveness to an intervention and feasibility. 
 
Our international SONG-Tx Delphi survey has achieved clear consensus on high priority outcome 
domains to report in all trials involving kidney transplant recipients. These pertained to preservation 
of the graft and common life-threatening medical complications – cancer, infection, and 
cardiovascular disease. However, there is increasing emphasis on explicitly including patient-
reported outcomes, which may be inherent in graft survival and clinical complications. Further 
stakeholder engagement through consensus workshops is needed, to discuss the inclusion of patient-
reported outcomes, and to ascertain appropriate, feasible, and acceptable approaches for establishing 
core outcome domains in kidney transplantation. We will present the findings from the Delphi survey 
at SONG-Tx consensus workshops for review and discussion by patients, caregivers, clinicians, 
researchers, and policy makers. Once the core outcome domains are established, subsequent work to 
identify core outcome measures will ensue, which may be informed from complementary initiatives 
such as the Clinical Data Interchange Standards Consortium (CDISC). CDISC recently published the 
Kidney Transplant Therapeutic Area User Guide (TAUG-KT) to facilitate standardized reporting of 
data. (50) 
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Improving the consistency and relevance of trial endpoints in kidney transplantation can ultimately 
empower patients and clinicians to make critical treatment decisions based on outcomes that 
explicitly matter to them.  
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Figure legends 
Figure 1. Consensus criteria and outcome domains 
Outcomes included in the potential core outcome set met at least two of the following criteria: mean 
score of greater than or equal to 7.5; mean score greater than or equal to 8; proportion of participants 
rating the outcome 7 to 9 (critically important) is greater than or equal to 75, and the median is less 
than 10 based on the forced ranking question. 
Figure 2. Mean scores of patients/caregivers in rounds 1-3 
Figure 3. Mean scores of health professionals in rounds 1-3 
Figure 4. Differences in mean scores between patients/caregivers and health professionals in rounds 
1-3 
*The top eight outcome domains for both stakeholder groups that met at least two of the following 
criteria: mean score of greater than or equal to 7.5; mean score greater than or equal to 8; proportion 
of participants rating the outcome 7 to 9 (critically important) is greater than or equal to 75, and the 
median is less than 10 based on the forced ranking question. 
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Table 1a. Characteristics of patients/caregivers  
Characteristic Round 1, n (%) Round 2, n (%) Round 3, n (%) 461 participants 387 participants 360 participants  
Participant typea    
 Patient 381 (82.3) 325 (83.5) 300 (82.9) 
 Caregiver/family member 35 (7.6) 28 (7.2) 27 (7.5) 
 Kidney donor 47 (10.1) 36 (9.3) 35 (9.6) 
Gender    
 Male 211 (45.8) 182 (47.0) 173 (48.1) 
 Female 250 (54.2) 205 (53.0) 187 (51.9) 
Age group (years)    
 18 – 40  71 (15.4) 52 (13.4) 48 (13.4) 
 41 – 50 119 (25.8) 95 (24.5) 86 (23.9) 
 51 – 60 138 (29.9) 120 (31.0) 111 (30.8) 
 61 – 70  113 (24.5) 102 (26.4) 97 (26.9) 
 ≥ 71 20 (4.3) 18 (4.7) 18 (5.0) 
Marital status    
 Single 70 (15.2) 62 (16.0) 56 (15.6) 
 Partner/de-facto 38 (8.3) 31 (8.0) 27 (7.5) 
 Married 307 (66.6) 257 (66.4) 241 (66.9) 
 Divorced/separated/widowed        46 (10.0) 34 (9.5) 36 (10.0) 
Number of children    
 0 157 (34.1) 137 (35.4) 130 (36.1) 
 1-2 212 (46.0) 172 (44.4) 162 (45.0) 
 > 3 92 (20.0) 78 (20.2) 69 (18.9) 
Employment status    
 Employed 261 (56.6) 210 (54.3) 192 (53.3) 
 Unemployed 40 (8.7) 34 (8.8) 30 (8.3) 
 Retired 110 (23.9) 101 (26.1) 98 (27.2) 
 Student or other 50 (10.9) 43 (10.7) 40 (11.1) 
Education    
 Did not complete high school 91 (19.7) 77 (19.9) 70 (19.4) 
 High school graduate 55 (11.9) 43 (11.1) 40 (11.1) 
 Professional certificate 109 (23.6) 89 (23.0) 86 (23.9) 
 Undergraduate degree 131 (28.4) 110 (28.4) 101 (28.1) 
 Postgraduate degree 75 (16.3) 68 (17.6) 63 (17.5) 
Current type of treatment    
 Kidney transplant from a deceased donor 189 (49.6) 168 (51.7) 160 (53.3) 
 Kidney transplant from a living donor 124 (32.5) 97 (29.8) 91 (30.3) 
 Haemodialysis 39 (10.2) 34 (10.5) 28 (9.3) 
 Peritoneal dialysis 7 (1.8) 6 (1.8) 4 (1.3) 
 No renal replacement therapy 22 (5.8) 20 (6.2) 17 (5.7) 
Years on transplantation    
 0 122 (26.5) 99 (25.6) 88 (24.4) 
 < 1 37 (8.0) 32 (8.3) 29 (8.1) 
 1-5 105 (22.8) 90 (23.2) 86 (23.9) 
 6-10 68 (14.7) 60 (15.5) 56 (15.5) 
 > 10 129 (28.0) 106 (27.4) 101 (28.1) 
Number of kidney transplants      
 0 122 (26.5) 99 (25.6) 88 (24.4) 
 1 283 (61.4) 242 (62.5) 228 (63.3) 
 2 41 (8.9) 35 (9.1) 33 (9.2) 
 > 3 15 (3.2) 11 (2.8) 11 (3.1) 
Cause of kidney disease    
 Diabetes 20(5.2) 19 (5.8) 19 (6.2) 
 Glomerulonephritis 95(24.6) 79 (23.9) 75 (24.6) 
 Polycystic kidney disease or inherited 102(26.4) 94 (28.5) 85 (27.9) 
 Other 129 (33.4) 105 (31.8) 99 (32.5) 
 Unknown 40 (10.4) 33 (10.0) 27 (8.9) 
Country    
 Australia 198 (42.9) 176 (45.5) 167 (46.4) 
 United Kingdom 70 (15.2) 59 (15.2) 55 (15.3) 
 New Zealand 32 (6.9) 27 (7.0) 26 (7.2) 
 United States 38 (8.2) 27 (7.0) 23 (6.4) 
 Other* 123 (26.7) 98 (25.3) 89 (24.7) 
aSome have multiple roles; *Other includes 22 countries: South Africa, Canada, Denmark, Ireland, China, Netherlands, 
Czech Republic, Greece, Spain, Austria, Belgium, Brazil, Cyprus, Finland, Georgia, Germany, Libya, Luxembourg, 
Poland, Slovenia, Turkey and Uruguay. NB. Percentages may not equal 100% due to rounding or duplicate categories. 
Respondents who do not complete round 2 cannot complete round 3.  
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Table 2. Characteristics of health professionals 
Characteristic Round 1, n (%) Round 2, n (%) Round 3, n (%) 557 participants 457 participants 419 participants 
Participant typea    
 Nephrologist 371 (58.3) 301 (56.4) 281 (56.7) 
 Surgeon 33 (5.2) 24 (4.5) 22 (4.4) 
 Nurse 66 (10.4) 59 (11.0) 49 (9.9) 
 Psychiatrist 2 (0.3) 2 (0.4) 2 (0.4) 
 Psychologist 2 (0.3) 2 (0.4) 2 (0.4) 
 Social Worker 6 (1.0) 6 (1.1) 5 (1.0) 
 Dietician 7 (1.1) 7 (1.3) 6 (1.2) 
 Researcher 75 (11.8) 69 (12.9) 61 (12.3) 
 Pharmacist 18 (2.9) 14 (2.6) 10 (2.0) 
 Policy maker 12 (1.9) 11 (2.1) 10 (2.0) 
 Industry 5 (0.8) 4 (0.7) 2 (0.4) 
 Others 40 (6.3) 35 (6.6) 26 (5.2) 
Gender    
 Male 308 (55.3) 250 (54.7) 233 (55.6) 
 Female 249 (44.7) 207 (45.3) 186 (44.4) 
Age group (years)    
 18 - 40  166 (29.8) 137 (30.0) 116 (27.7) 
 41 – 50 177 (31.8) 142 (31.1) 132 (31.5) 
 51 – 60 156 (28.0) 130 (28.4) 126 (30.1) 
 61 – 70  52 (9.3) 43 (9.4) 40 (9.5) 
 ≥ 71 6 (1.1) 5 (1.1) 5 (1.2) 
Experience in transplantation (years)    
 ≤10 207 (37.2) 159 (34.8) 134 (32.0) 
 11-20 183 (32.9) 156 (34.1) 150 (35.8) 
 ≥ 21 167 (30.0) 142 (31.1) 135 (32.2) 
No. of transplantation trials as investigators    
 0 250 (44.9) 207 (45.3) 185 (44.2) 
 1-5 180 (32.3) 151 (33.0) 140 (33.4) 
 6-10 58 (10.4) 46 (10.1) 42 (10.0) 
 ≥ 11 69 (12.4) 53 (11.6) 52 (12.4) 
Specific role in kidney transplant researcha    
 Government, policy making 94 (19.5) 80 (20.0) 78 (20.5) 
 Clinical practice guidelines 226 (47.0) 185 (463) 178 (46.7) 
 Funding (grant reviewer, panel) 126 (26.2) 106 (26.5) 100 (26.2.) 
 Other 35 (7.3) 29 (7.3) 25 (6.6) 
Country*    
 Australia 70 (12.6) 58 (12.7) 54 (12.9) 
 United states 66 (11.8) 52 (11.4) 46 (11.0) 
 Canada 53 (9.5) 44 (9.6) 40 (9.5) 
 New Zealand 39 (7.0) 38 (8.3) 37 (8.8) 
 United Kingdom 36 (6.5) 31 (6.8) 30 (7.2) 
 France 34 (6.1) 27 (5.9) 25 (6.0) 
 Spain 23 (4.1) 19 (4.2) 17 (4.1) 
 China and Hong Kong 19 (3.4) 14 (3.1) 12 (2.9) 
 Italy 13 (2.3) 9 (2.0) 7 (1.7) 
 Netherland 12 (2.2) 9 (2.0) 8 (1.9) 
 Brazil 12 (2.2) 11 (2.4) 9 (2.1) 
 Other* 180 (32.3) 145 (31.7) 134 (32.0) 
aSome have multiple roles. *Other includes 64 countries: Austria, Belgium, Germany, Portugal, India, Romania, Egypt, 
Greece, Saudi Arabia, Finland, Mexico, Switzerland, Argentina, Colombia, Sweden, Japan, Montenegro, Poland, Serbia, 
Thailand, Vietnam, Cameroon, Chile, Croatia, Denmark, Kosovo, Lithuania, Nigeria, Norway, Oman, Singapore, Slovakia, 
Slovenia, South Africa, Turkey, Ukraine, United Arab Emirates, Algeria, Bangladesh, Bolivia, Bulgaria, Cape Verde, Chad, 
Czech Republic, Ecuador, Guatemala, Honduras, Hungary, Iran, Ireland, Jordan, Kenya, Korea South, Luxembourg, 
Macedonia, Malaysia, Myanmar, Pakistan, Panama, Philippines, Sri Lanka, Taiwan, Trinidad & Tobago and Venezuela. 
NB. Percentages may not equal 100% due to rounding or duplicate categories.
  
Table 3. Selected illustrative quotations 
Theme 
Capacity to control and inevitability 
Patients/caregivers 
Skin cancer is an acceptable risk for having a functional graft. With proper surveillance by the patient/carer it can be treated effectively. (cancer – skin) 
This is not necessarily life threatening and can be treated. (high cholesterol) 
Patient should be aware and act accordingly, if they don't it's nobody's doing but their own. (sun sensitivity) 
I determine my outcome and health every day. If I don’t look after myself, I must be able to cope with what happens then. I might not suffer, my family and friends are the ones who suffer. (graft 
loss) 
Death is inevitable at some stage for all us however we need to be realistic that a transplant is not a cure for kidney disease, it is a preferable treatment to dialysis and gives one quality of life for 
the duration that the graft lasts. I believe a lot depends on how you look after yourself post-transplant. (death) 
I agree with the comment that it's a silent killer but I have rated this 1. I have my own BP machine and I keep an eye on it. Again, it comes back to what I eat and my exercise. It is my responsibility 
to check my BP. Making yourself knowledgeable about your health is important. (blood pressure) 
It is an important problem but can be treated successfully. (acute graft rejection)   
Important but not critical. If you're going to die you're going to die and if you've had a transplant you've at least lived longer, even if you're on dialysis every night you are still alive, be grateful. 
(death)  
I've changed my views on this as most skin cancers can be removed fairly quickly removed before they spread. (cancer – skin)    
Health professionals 
Known and generally control pretty good these days. (blood pressure) 
Clearly important but largely acute rejection has been shown to be generally reversible and treatable.  Less important area for research in my opinion. (acute graft rejection)  
Clearly of critical importance in the balance with rejection. However most infections are rather easy to treat or preventable, causing less problems nowadays so it is not as critical anymore. But 
clearly infection may directly cause graft loss and death, and treatment may be costly, require hospitalizations and have side effects. (infection) 
I changed my answer. It´s critical, but experienced surgeons make miracles happen. (surgical complications)                                                                                                                 
Personal relevance 
Patients/caregivers 
Depends on age and circumstances but is an indication that life is as normal as possible. (ability to work) 
I have moved this up because although not something I am particularly dealing with, I can see that it would be massive for many patients dealing with the transition. (depression) 
For patients of working age, this must be the single most important outcome measure, since it is also a surrogate indicator of the success of all other outcome measures. (ability to work) 
I'm retired, even through all the years I was working, I never found my health restricting work. It’s very much a state of mind. I’m keeping my score of 1. (ability to work) 
A very personal perspective based on personal experience having not experienced most of outcomes but hopefully sympathetic to those who might have. (general) 
Health professionals 
Particularly for fertile women, this is critical. (fertility) 
Appears to be a more important outcome for patients than health professionals. Reflects quality of life, which has a substantial impact. (fatigue) 
Debilitating repercussions 
Patients/caregivers 
A potentially devastating impact on the transplanted patient and need to be given a higher priority. (cancer – other) 
Fear of having to return to dialysis is worse than fear of death. (graft loss) 
I don't know why I did not rate this higher the first time around. The thought of dialysis as a way of life is why we did a live kidney donation. Not sure how we will cope. (graft loss) 
  
Slightly lowered my importance rating.  As confidence grew in my transplant and able to enjoy a 'normal' life, depression improved. It is important as don't want to waste any more life being 
depressed. Need to be able to make the most of life and embrace all the new opportunities and good health. (depression) 
Always concerned about the likelihood of this as a patient. It is a large and real fear. (surgical complications) 
Health professionals 
This is a major cause of death and impacts on how the patient feels functions survives. (infection) 
Extremely important as a surrogate endpoint for severe medical problems and side effects or poor function. (hospitalization) 
Critical, but relative to death cannot receive the highest rating. (graft loss) 
Understanding and gaining awareness of risks 
Patients/caregivers 
Wasn't aware that this was a possible problem. (diabetes) 
I was never aware a transplant could make one impotent. (fertility) 
I have changed my score based on health professionals’ judgments. (chronic graft rejection) 
On second thought I find this is a really important issue, affecting quality of life and also stress related to going back on dialysis. (chronic graft rejection) 
I have increased my score since last survey have done some research on this outcome and believe it is an issue that needs more investigation. (cancer – other) 
Certainly can be a major risk factor, feel it needs to be rated up so people appreciate just how critical it can be to people staying healthy. (infection) 
More common than I realized. (cancer – skin)  
I have moved my rating to 8 because this is obviously so important to patients. (depression)  
I found little to change my opinions. Where I have it's because the additional perspectives provided by everyone's comments have enlightened me. (general) 
I'm finding it very instructive to learn what my fellow transplant patients’ value most about renal and transplant care. My experience of the process is similar to many, but unique from some as well. 
Good food for thought in improving kidney care across the spectrum: there is a need to understand the patients perspective and their individual needs and goals in living with it. (round 2)  
Health professionals 
Important but not specific for transplant, eventually associated with complications and fear of graft loss. (depression) 
Accept comments and respect importance for patients, so I have moved this to 8. (depression) 
Underestimated the importance based on patient feedback. (eye problems) 
Addressing critical knowledge gaps 
Patients/caregivers 
Research would be beneficial in providing the family / friends with the most accurate prognosis and expectations. (impact on family) 
I was going to rank this with lower importance than I have but if we know answers to this we have more opportunities to find out the reasons why. This would help understanding of rejection and if 
anything can be done to improve survival rates. (death) 
The more we know about this the more we can prevent it from happening. (graft loss) 
I feel strongly that research into chronic graft loss is essential for finding new protocols and medications. (chronic graft loss) 
From all the comments it is clear it is a major issue and critical to understand more in order to prevent skin cancers as well as treat it. The research may help us design education (for both health 
professionals and patients) and may lead to new insight. (cancer – skin) 
My rating stands as research plays a big role here so they can keep ahead of these infections so the new kidney transplant is kept functioning longer. (infection) 
Health professionals 
This is complex but is a major problem requiring solution if we are to improve outcomes. (chronic graft rejection) 
This has been a long-standing issue. Getting patients off the disability pension and into the work force after transplant is often difficult. (ability to work) 
Very critical for patient but hard to assess, needs long-term data hard to generate and information on pre-kidney transplantation data. (bone disease) 
  
Very important to recognize, so that we can learn how to treat and give prognosis. (chronic graft rejection) 
Key issue, not easy to address, but deserves specific research as no clear data are available on this outcome. (ability to work)  
NB: In general, the comments were entered as a general comment at the end of the survey not for a specific outcome domain. 
